A61K 47/6831
Fungal toxins
Official title: {Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin}
A61K47/6831 (Fungal toxins) appears on 86 US grants and 168 published applications in this corpus.
Search patents in A61K- Granted patents
- 86
- Published applications
- 168
- Assignees
- 61
- Inventors
- 314
- Latest grant
- 7 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 2 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 3 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 3 | 0 |
| 2002 | 3 | 5 |
| 2003 | 4 | 2 |
| 2004 | 1 | 0 |
| 2005 | 0 | 0 |
| 2006 | 1 | 2 |
| 2007 | 0 | 2 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 1 |
| 2011 | 1 | 1 |
| 2012 | 2 | 3 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 1 | 1 |
| 2016 | 1 | 6 |
| 2017 | 0 | 4 |
| 2018 | 3 | 7 |
| 2019 | 4 | 12 |
| 2020 | 7 | 16 |
| 2021 | 5 | 25 |
| 2022 | 4 | 18 |
| 2023 | 8 | 13 |
| 2024 | 6 | 21 |
| 2025 | 17 | 13 |
| 2026 | 4 | 14 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Amatoxin antibody-drug conjugates and uses thereof7 Apr 2026US 12,595,284 B2Heidelberg Pharma Research GmbH
- Antibody drug conjugates with cleavable linkers17 Mar 2026US 12,576,158 B2Heidelberg Pharma Research GmbH
- Methods of use of anti-CD45 antibodies and conjugates thereof10 Mar 2026US 12,570,756 B2Regeneron Pharmaceuticals, Inc.
- Targeted amatoxin conjugate for the treatment of solid tumors10 Feb 2026US 12,544,419 B2Heidelberg Pharma Research GmbH
- Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers30 Dec 2025US 12,508,321 B2Hangzhou Dac Biotech Co., Ltd.
- Modified amatoxins and uses thereof3 Sep 2026US 2026/0258086 A1The University of British Columbia
- Amatoxin antibody-drug conjugates and uses thereof13 Aug 2026US 2026/0234192 A1Heidelberg Pharma Research GmbH
- An antibody-drug conjugate having two or more functional small molecule compounds for enhanced treatment of refractory diseases16 Jul 2026US 2026/0199510 A1Hangzhou Dac Biotech Co., Ltd.
- Compositions and methods for protein internalization9 Jul 2026US 2026/0191983 A1Lytica Therapeutics, Inc.
- Bcma monoclonal antibody and the antibody-drug conjugate11 Jun 2026US 2026/0158153 A1Hangzhou Dac Biotech Co., Ltd.
Most cited
By later US patents
- Therapeutic inhibitor of vascular smooth muscle cells562US 5,733,925 ANeoRx Corporation · 1998
- Therapeutic inhibitor of vascular smooth muscle cells438US 5,981,568 ANeoRx Corporation · 1999
- Therapeutic inhibitor of vascular smooth muscle cells308US 6,074,659 ANoeRx Corporation · 2000
- Therapeutic inhibitor of vascular smooth muscle cells280US 5,811,447 ANeoRx Corporation · 1998
- Therapeutic inhibitor of vascular smooth muscle cells245US 6,171,609 B2NeoRx Corporation · 2001